MA27671A1 - Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement - Google Patents
Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquementInfo
- Publication number
- MA27671A1 MA27671A1 MA28526A MA28526A MA27671A1 MA 27671 A1 MA27671 A1 MA 27671A1 MA 28526 A MA28526 A MA 28526A MA 28526 A MA28526 A MA 28526A MA 27671 A1 MA27671 A1 MA 27671A1
- Authority
- MA
- Morocco
- Prior art keywords
- rapamycin
- treatment
- combination
- pharmaceutical compositions
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention porte sur des compositions pharmaceutiques comprenant en combinaison la rapamycine ou un dérivé de rapamycine et un composé de formule (I), ces compositions pouvant être utiles dans le traitement de maladies inflammatoires et de maladies induites immunologiquement, telles que les maladies auto-immunes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0306070A GB0306070D0 (en) | 2003-03-17 | 2003-03-17 | Organic compounds |
GB0306868A GB0306868D0 (en) | 2003-03-25 | 2003-03-25 | Organic compounds |
GB0319226A GB0319226D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27671A1 true MA27671A1 (fr) | 2005-12-01 |
Family
ID=33032928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28526A MA27671A1 (fr) | 2003-03-17 | 2005-09-30 | Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement |
Country Status (26)
Country | Link |
---|---|
US (1) | US20060154952A1 (fr) |
EP (1) | EP1608368B8 (fr) |
JP (1) | JP2006515017A (fr) |
KR (1) | KR100855140B1 (fr) |
AR (1) | AR043504A1 (fr) |
AT (1) | ATE409479T1 (fr) |
AU (1) | AU2004222563B2 (fr) |
BR (1) | BRPI0408423A (fr) |
CA (2) | CA2633287A1 (fr) |
CL (1) | CL2004000535A1 (fr) |
DE (1) | DE602004016830D1 (fr) |
EC (1) | ECSP056006A (fr) |
ES (1) | ES2315648T3 (fr) |
HK (1) | HK1086743A1 (fr) |
HR (1) | HRP20050800A2 (fr) |
IS (1) | IS8028A (fr) |
MA (1) | MA27671A1 (fr) |
MX (1) | MXPA05009934A (fr) |
MY (1) | MY137868A (fr) |
NO (1) | NO20054778L (fr) |
PE (1) | PE20050313A1 (fr) |
PL (1) | PL1608368T3 (fr) |
PT (1) | PT1608368E (fr) |
TN (1) | TNSN05197A1 (fr) |
TW (2) | TW200835484A (fr) |
WO (1) | WO2004082681A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1804779A1 (fr) * | 2004-10-28 | 2007-07-11 | Wyeth | Utilisation d'un inhibiteur mtor dans le traitement de leiomyomes uterins |
CA2719134C (fr) * | 2008-03-21 | 2015-06-30 | The University Of Chicago | Traitement avec des antagonistes des opioides et des inhibiteurs mtor |
AU2013205002B2 (en) * | 2008-03-21 | 2016-09-15 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
ES2825173T3 (es) | 2009-01-21 | 2021-05-14 | Amgen Inc | Composiciones y métodos de tratamiento de enfermedades inflamatorias y autoinmunitarias |
RU2449806C1 (ru) * | 2010-11-30 | 2012-05-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ лечения красного плоского лишая слизистой оболочки полости рта |
WO2014117035A1 (fr) | 2013-01-24 | 2014-07-31 | Transderm, Inc. | Compositions pour une administration transdermique d'inhibiteurs de mtor |
RU2707285C2 (ru) | 2013-10-08 | 2019-11-26 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Рапамицин для лечения лимфангиолейомиоматоза |
HRP20230863T1 (hr) * | 2014-04-04 | 2023-11-10 | AI Therapeutics, Inc. | Inhalacijska formulacija rapamicina, namijenjena liječenju stanja povezanih sa starenjem |
EP3209330B1 (fr) | 2014-10-07 | 2022-02-23 | AI Therapeutics, Inc. | Formulation inhalable comprenant du sirolimus pour le traitement de l'hypertension pulmonaire |
TN2017000432A1 (en) | 2015-04-10 | 2019-04-12 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
CA3049402A1 (fr) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Compositions anhydres d'inhibiteurs de mtor et methodes d'utilisation |
EP3817743A4 (fr) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU640963B2 (en) * | 1989-11-09 | 1993-09-09 | MEDA Pharma S.a.r.l | Heteroatoms-containing tricyclic compounds |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
PT956034E (pt) * | 1996-07-30 | 2002-12-31 | Novartis Ag | Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina |
GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
JP2005512946A (ja) * | 2001-05-09 | 2005-05-12 | ノバルティス アクチエンゲゼルシャフト | 選択的免疫調節法 |
CN1615137A (zh) * | 2002-01-10 | 2005-05-11 | 诺瓦提斯公司 | 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送*** |
AU2003240391B8 (en) * | 2002-05-09 | 2009-08-06 | Hemoteq Ag | Compounds and method for coating surfaces in a haemocompatible manner |
-
2004
- 2004-03-08 AR ARP040100730A patent/AR043504A1/es not_active Application Discontinuation
- 2004-03-15 PE PE2004000273A patent/PE20050313A1/es not_active Application Discontinuation
- 2004-03-15 TW TW097116133A patent/TW200835484A/zh unknown
- 2004-03-15 TW TW093106848A patent/TW200503703A/zh unknown
- 2004-03-16 PT PT04720871T patent/PT1608368E/pt unknown
- 2004-03-16 CA CA002633287A patent/CA2633287A1/fr not_active Abandoned
- 2004-03-16 MX MXPA05009934A patent/MXPA05009934A/es not_active Application Discontinuation
- 2004-03-16 AT AT04720871T patent/ATE409479T1/de not_active IP Right Cessation
- 2004-03-16 US US10/547,185 patent/US20060154952A1/en not_active Abandoned
- 2004-03-16 JP JP2005518678A patent/JP2006515017A/ja active Pending
- 2004-03-16 EP EP04720871A patent/EP1608368B8/fr not_active Expired - Lifetime
- 2004-03-16 MY MYPI20040914A patent/MY137868A/en unknown
- 2004-03-16 BR BRPI0408423-3A patent/BRPI0408423A/pt not_active IP Right Cessation
- 2004-03-16 CL CL200400535A patent/CL2004000535A1/es unknown
- 2004-03-16 AU AU2004222563A patent/AU2004222563B2/en not_active Ceased
- 2004-03-16 ES ES04720871T patent/ES2315648T3/es not_active Expired - Lifetime
- 2004-03-16 CA CA002517671A patent/CA2517671A1/fr not_active Abandoned
- 2004-03-16 PL PL04720871T patent/PL1608368T3/pl unknown
- 2004-03-16 DE DE602004016830T patent/DE602004016830D1/de not_active Expired - Fee Related
- 2004-03-16 KR KR1020057017469A patent/KR100855140B1/ko not_active IP Right Cessation
- 2004-03-16 WO PCT/EP2004/002714 patent/WO2004082681A1/fr active IP Right Grant
-
2005
- 2005-08-17 TN TNP2005000197A patent/TNSN05197A1/en unknown
- 2005-09-08 EC EC2005006006A patent/ECSP056006A/es unknown
- 2005-09-12 HR HR20050800A patent/HRP20050800A2/xx not_active Application Discontinuation
- 2005-09-15 IS IS8028A patent/IS8028A/is unknown
- 2005-09-30 MA MA28526A patent/MA27671A1/fr unknown
- 2005-10-17 NO NO20054778A patent/NO20054778L/no not_active Application Discontinuation
-
2006
- 2006-06-13 HK HK06106761.8A patent/HK1086743A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2315648T3 (es) | 2009-04-01 |
AU2004222563B2 (en) | 2006-11-02 |
KR100855140B1 (ko) | 2008-08-28 |
CA2633287A1 (fr) | 2004-09-30 |
JP2006515017A (ja) | 2006-05-18 |
EP1608368B1 (fr) | 2008-10-01 |
EP1608368A1 (fr) | 2005-12-28 |
MXPA05009934A (es) | 2006-03-21 |
DE602004016830D1 (de) | 2008-11-13 |
KR20050110023A (ko) | 2005-11-22 |
CL2004000535A1 (es) | 2005-01-14 |
PT1608368E (pt) | 2009-01-27 |
HK1086743A1 (en) | 2006-09-29 |
AU2004222563A1 (en) | 2004-09-30 |
HRP20050800A2 (en) | 2006-11-30 |
NO20054778L (no) | 2005-12-19 |
CA2517671A1 (fr) | 2004-09-30 |
TW200835484A (en) | 2008-09-01 |
ECSP056006A (es) | 2006-01-27 |
ATE409479T1 (de) | 2008-10-15 |
WO2004082681B1 (fr) | 2004-11-25 |
PE20050313A1 (es) | 2005-06-14 |
AR043504A1 (es) | 2005-08-03 |
TW200503703A (en) | 2005-02-01 |
IS8028A (is) | 2005-09-15 |
EP1608368B8 (fr) | 2009-06-10 |
WO2004082681A1 (fr) | 2004-09-30 |
BRPI0408423A (pt) | 2006-03-21 |
TNSN05197A1 (en) | 2007-06-11 |
US20060154952A1 (en) | 2006-07-13 |
MY137868A (en) | 2009-03-31 |
PL1608368T3 (pl) | 2009-03-31 |
NO20054778D0 (no) | 2005-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27671A1 (fr) | Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement | |
MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
MXPA05009595A (es) | Compuestos 7-amino-isoindolilo y sus usos farmaceuticos. | |
ATE371645T1 (de) | Naphthalinderivate, die sich an den ep4?rezeptor binden | |
DE602004013563D1 (de) | Rantagonisten | |
JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
MA32231B1 (fr) | Composés organiques | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA28269A1 (fr) | Arylpyrazoles substitués servant d'agents parasiticides | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
MA30207B1 (fr) | Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide | |
DE602004027021D1 (de) | Cgrp-rezeptorantagonisten | |
MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
MA29213B1 (fr) | Quinolones a substitution macrolones - amino | |
MA27661A1 (fr) | Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant | |
DE60206198D1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
MA32931B1 (fr) | Compositions antimicrobiennes | |
TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents |